Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for M68830112 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 | 5.0% |
8/14/2026
Event 6/30/2026
|
|
| Price T Rowe Associates Inc /MD/ 13G | 5.5% |
5/15/2026
Event 3/31/2026
|
|
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 | 4.3% |
2/17/2026
Event 12/31/2025
|
|
|
Yelin Lapidot Holdings Management Ltd.
13G/A
Amendment 1
|
6.0% |
2/5/2026
Event 12/31/2025
|
|
| Yelin Lapidot Holdings Management Ltd. | 6.0% | ||
| Dov Yelin | 6.0% | ||
| Yair Lapidot | 6.0% | ||
| Price T Rowe Associates Inc /MD/ 13G | 5.5% |
11/14/2025
Event 9/30/2025
|
|
|
Access Industries, LLC
13D/A
Amendment 6
|
11.6% |
10/3/2025
Event 9/30/2025
|
|
| Access Industries Holdings LLC | 11.6% | ||
| Access Industries, LLC | 11.6% | ||
| Access Industries Management, LLC | 11.6% | ||
| Clal Industries Ltd. | 11.6% | ||
| Clal Biotechnology Industries Ltd. | 11.6% | ||
| Clal Life Sciences L.P. | 9.2% | ||
| Len Blavatnik | 11.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 1.45 k | $20.0 k |
| 2026 Q2 | 82 | 5.82 M | $85.7 M |
| 2026 Q1 | 78 | 6.04 M | $97.3 M |
| 2025 Q4 | 80 | 6.22 M | $115 M |
| 2025 Q3 | 79 | 5.78 M | $104 M |
| 2025 Q2 | 73 | 4.44 M | $86.0 M |
| 2025 Q1 | 69 | 4.29 M | $66.6 M |
| 2024 Q4 | 66 | 4.43 M | $79.0 M |
| 2024 Q3 | 69 | 4.21 M | $76.0 M |
| 2024 Q2 | 52 | 2.73 M | $42.4 M |
| 2024 Q1 | 38 | 2.27 M | $32.4 M |
| 2023 Q4 | 25 | 2.52 M | $25.6 M |
| 2023 Q3 | 20 | 2.04 M | $21.8 M |
| 2023 Q2 | 21 | 2.05 M | $21.8 M |
| 2023 Q1 | 22 | 1.98 M | $26.4 M |
| 2022 Q4 | 21 | 779 k | $10.5 M |